Table 2.
Grade 3 or higher treatment-related adverse events
| Event | During FOLFIRINOX | During IMRT/Gemcitabine | Total (N = 25) |
|---|---|---|---|
| All hematologic AEs | n | n | n (%) |
| Neutropenia | 3 | 7 | 10 (40) |
| Leukopenia | 0 | 8 | 8 (32) |
| Lymphopenia | 1 | 7 | 8 (32) |
| Febrile neutropenia | 2 | 0 | 2(8) |
| Anemia | 0 | 2 | 2 (8) |
| Nonhematologic AEs | |||
| Nausea | 4 | 1 | 5 (20) |
| Vomiting | 3 | 2 | 5 (20) |
| Diarrhea | 3 | 1 | 4(16) |
| Fatigue | 2 | 1 | 3 (12) |
| Abdominal pain | 1 | 1 | 2 (8) |
| Oral mucositis / esophagitis | 2 | 0 | 2 (8) |
| AST / ALT increased | 0 | 2 | 2 (8) |
| Anorexia | 0 | 1 | 1 (4) |
| Chest pain / coronary spasm | 1 | 0 | 1 (4) |
| Cardiac arrest / death | 1 | 0 | 1 (4) |
| Cholangitis | 1 | 0 | 1 (4) |
| Gastric perforation | 0 | 1 | 1 (4) |
Abbreviations: AE = adverse event; ALT = alanine transaminase; AST = aspartate transaminase.